PB

Peter Bullard

Senior Vice President Manufacturing at BioCina

Peter Bullard is an experienced manufacturing leader with a career spanning over two decades in the pharmaceutical industry. Since January 2025, Peter has served as Senior Vice President of Manufacturing at BioCina, after holding the same role at NovaCina from April 2023 to January 2025. Peter's extensive tenure at Pfizer from April 2003 to April 2023 included roles such as Manufacturing Leader, Operational Excellence Leader, and Continuous Improvement Manager, during which responsibility for implementing the Lean Management System at the Perth manufacturing site was held. Prior experience includes positions at Pharmacia as Validation Supervisor and at Delta West as Senior Validation Officer, marking a solid foundation in validation and manufacturing processes.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


BioCina

BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA and Health Canada. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award. Learn more at https://biocina.com.


Employees

51-200

Links